Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum RXi Pharmaceuticals Corp RXII

"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Bullboard (NDAQ:RXII)

View:
Post by campston Apr 17, 2015 9:03am

Big News!

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology that address high-unmet ...more  
Post by mersoleil11on Mar 28, 2015 8:14am

RXii and MirImmune Licence Exclusive Agreement

https://finance.yahoo.com/news/rxi-pharmaceuticals-mirimmune-llc-enter-130200653.html " MirImmune LLC, today announced that they have entered into an exclusive license agreement to RXi' ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities